StockNews.com Lowers Aspira Women’s Health (NASDAQ:AWH) to Sell

Aspira Women’s Health (NASDAQ:AWH) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a report released on Thursday.

Separately, Alliance Global Partners cut their target price on Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating for the company in a research note on Wednesday, August 14th.

Aspira Women’s Health Stock Performance

Shares of NASDAQ:AWH opened at $0.85 on Thursday. The company’s 50-day moving average is $1.18 and its 200 day moving average is $2.23. The company has a market capitalization of $13.67 million, a P/E ratio of -0.59 and a beta of 1.48. Aspira Women’s Health has a fifty-two week low of $0.81 and a fifty-two week high of $6.57.

Aspira Women’s Health (NASDAQ:AWH) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. The firm had revenue of $2.42 million during the quarter, compared to the consensus estimate of $2.60 million. During the same quarter in the prior year, the firm posted ($0.28) earnings per share. As a group, research analysts predict that Aspira Women’s Health will post -1.26 earnings per share for the current year.

Hedge Funds Weigh In On Aspira Women’s Health

An institutional investor recently raised its position in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. raised its position in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) by 43.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 179,371 shares of the company’s stock after acquiring an additional 53,997 shares during the period. B. Riley Wealth Advisors Inc. owned approximately 1.73% of Aspira Women’s Health worth $732,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 12.19% of the stock is owned by hedge funds and other institutional investors.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.